We have located links that may give you full text access.
Journal Article
Review
Pemetrexed for the treatment of non-small-cell lung cancer.
Expert Review of Anticancer Therapy 2009 September
Pemetrexed is a novel multi-targeted antifolate that is used in the treatment of both malignant pleural mesothelioma and non-small-cell lung cancer (NSCLC). Lung cancer is the most common cancer in the world and NSCLC represents approximately 80% of all lung cancers. Pemetrexed is the first NSCLC drug for which 'treatment-by-histology' has been determined. This refers to the greater efficacy of pemetrexed in patients with advanced NSCLC other than of predominantly squamous-cell histology. The advent of treatment-by-histology represents a significant step forward in the treatment of lung cancer, allowing physicians to tailor therapies to the individual patient. Ongoing trials aim to establish the place of pemetrexed in maintenance, in combination with other 'targeted agents', in adjuvant therapy in early NSCLC and in concurrent radio/chemotherapy.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app